Chris Spivey

At INTERPHEX 2024, Susan Schniepp, distinguished fellow, Regulatory Compliance Associates, and co-chair of board of directors, Parenteral Drug Association, explores the impact of QMS on quality maturity.

Bill Whitford, Strategic Solutions leader at Arcadis, reviews the progress made in 3D bioprinting toward commercial biologics production at INTERPHEX 2024.

Cellares CEO Fabian Gerlinghaus explores advancements in counterflow centrifugal elutriation and electroporation, teasing exciting developments in product testing.

Accurately targeted immunotherapies through reliable neoantigen recognition enable personalized medicine development.

A tidal wave of questions floats the need for more upstream automation.

Steffen Thirstrup, chief medical officer, EMA, emphasizes the importance of transparency in investigating potential safety issues of CAR-T therapies, while highlighting the need to balance regulatory diligence with maintaining trust within the community and among stakeholders.

Steffen Thirstrup, chief medical officer of the EMA, discusses manufacturing supply, drug shortages, commercial incentives, politics, and patient wellbeing.

In surplus and shortage, compounding amplifies all.

An interview with Steffen Thirstrup, chief medical officer, European Medicines Agency (EMA).

SUS aids biopharma manufacturers to overcome the rigidity of more traditional stainless-steel technologies.